N T Ayas1,2,3,4, A J Hirsch Allen5,6, N Fox5, B Peres6,7, M Mehrtash5, K H Humphries8, R Jen5,9, C M Taylor8, S F van Eeden9. 1. Leon Judah Blackmore Centre for Sleep Disorders, University of British Columbia (UBC), Vancouver, Canada. nayas@providencehealth.bc.ca. 2. Respiratory Division, Department of Medicine, UBC, Vancouver, Canada. nayas@providencehealth.bc.ca. 3. Canadian Sleep and Circadian Network, Montreal, Canada. nayas@providencehealth.bc.ca. 4. Diamond Centre, 7th Floor, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada. nayas@providencehealth.bc.ca. 5. Leon Judah Blackmore Centre for Sleep Disorders, University of British Columbia (UBC), Vancouver, Canada. 6. Canadian Sleep and Circadian Network, Montreal, Canada. 7. Department of Oral Health Sciences, Faculty of Dentistry, UBC, Vancouver, Canada. 8. Division of Cardiology, Department of Medicine, UBC, Vancouver, Canada. 9. Respiratory Division, Department of Medicine, UBC, Vancouver, Canada.
Abstract
PURPOSE: Patients with obstructive sleep apnea (OSA) are at increased risk of cardiovascular and cerebrovascular disease (CVD) but it is unclear who are at greatest risk. We determined whether the inflammatory marker, C-reactive protein (CRP), could be a useful prognostic biomarker. METHODS: Adult patients referred for polysomnography (PSG) with OSA were studied. Serum CRP levels were measured using ELISA the morning after PSG. Validated CV events within 4 years of PSG were ascertained by linking to provincial research datasets. RESULTS: 155 patients with OSA (AHI ≥ 5/h) had CRP measured. Median age was 53 and median AHI was 21/h. 10 patients (7.1%) suffered at least one event, but rates varied substantially by CRP (0/35 patients in the lowest quartile, and 7/39 in the highest CRP quartile). In the unadjusted analysis, patients in the highest CRP quartile (≥ 2.38 mg/L) were significantly more likely to suffer an event (odds ratio = 9.72 (95% CI 2.43-38.84), p = 0.001). CRP continued to be a significant predictor after controlling for multiple confounders. OSA severity and desaturation were not significantly associated with prospective events. CONCLUSIONS: In this small preliminary study, OSA patients with an elevated CRP were significantly more likely to suffer a CVD event in the 4 years after PSG. Although these findings need to be confirmed in larger prospective cohorts, CRP may be useful in risk stratifying OSA patients to guide therapy or to identify patients that might be most appropriate for clinical trials of CVD prevention.
PURPOSE:Patients with obstructive sleep apnea (OSA) are at increased risk of cardiovascular and cerebrovascular disease (CVD) but it is unclear who are at greatest risk. We determined whether the inflammatory marker, C-reactive protein (CRP), could be a useful prognostic biomarker. METHODS: Adult patients referred for polysomnography (PSG) with OSA were studied. Serum CRP levels were measured using ELISA the morning after PSG. Validated CV events within 4 years of PSG were ascertained by linking to provincial research datasets. RESULTS: 155 patients with OSA (AHI ≥ 5/h) had CRP measured. Median age was 53 and median AHI was 21/h. 10 patients (7.1%) suffered at least one event, but rates varied substantially by CRP (0/35 patients in the lowest quartile, and 7/39 in the highest CRP quartile). In the unadjusted analysis, patients in the highest CRP quartile (≥ 2.38 mg/L) were significantly more likely to suffer an event (odds ratio = 9.72 (95% CI 2.43-38.84), p = 0.001). CRP continued to be a significant predictor after controlling for multiple confounders. OSA severity and desaturation were not significantly associated with prospective events. CONCLUSIONS: In this small preliminary study, OSA patients with an elevated CRP were significantly more likely to suffer a CVD event in the 4 years after PSG. Although these findings need to be confirmed in larger prospective cohorts, CRP may be useful in risk stratifying OSA patients to guide therapy or to identify patients that might be most appropriate for clinical trials of CVD prevention.
Authors: Richard J Schwab; Safwan M Badr; Lawrence J Epstein; Peter C Gay; David Gozal; Malcolm Kohler; Patrick Lévy; Atul Malhotra; Barbara A Phillips; Ilene M Rosen; Kingman P Strohl; Patrick J Strollo; Edward M Weaver; Terri E Weaver Journal: Am J Respir Crit Care Med Date: 2013-09-01 Impact factor: 21.405
Authors: Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn Journal: N Engl J Med Date: 2017-08-27 Impact factor: 91.245
Authors: Kathleen F Kerr; Jeremy Roth; Kehao Zhu; Heather Thiessen-Philbrook; Allison Meisner; Francis Perry Wilson; Steven Coca; Chirag R Parikh Journal: Clin Trials Date: 2017-08-10 Impact factor: 2.486
Authors: Richard B Berry; Rohit Budhiraja; Daniel J Gottlieb; David Gozal; Conrad Iber; Vishesh K Kapur; Carole L Marcus; Reena Mehra; Sairam Parthasarathy; Stuart F Quan; Susan Redline; Kingman P Strohl; Sally L Davidson Ward; Michelle M Tangredi Journal: J Clin Sleep Med Date: 2012-10-15 Impact factor: 4.062
Authors: A J Hirsch Allen; Ali Abdul Ghafoor; Yu Liu; Andrew Sandford; Rachel Jen; Patrick Daniele; Carolyn Taylor; Bernardo U Peres; Najib T Ayas Journal: Sleep Breath Date: 2022-06-07 Impact factor: 2.816
Authors: A J Hirsch Allen; Rachel Jen; Diego R Mazzotti; Brendan T Keenan; Sebastian D Goodfellow; Carolyn M Taylor; Patrick Daniele; Bernardo Peres; Yu Liu; Morvarid Mehrtash; Najib T Ayas Journal: J Clin Sleep Med Date: 2022-09-01 Impact factor: 4.324
Authors: Anna C Rivara; Margaret Corley; Courtney C Choy; Rachel L Duckham; Alysa Pomer; Muagututia Sefuiva Reupena; Satupaitea Viali; Take Naseri; Erin E Kershaw; Scott E Crouter; Stephen T McGarvey; Richard G Bribiescas; Claudia Valeggia; Nicola L Hawley Journal: Am J Hum Biol Date: 2021-07-14 Impact factor: 1.937